Treatment summary
| Variable . | Total . | Skin only . | Systemic only without skin . | Skin and systemic . | Incomplete staging . | P* . |
|---|---|---|---|---|---|---|
| N | 44 | 10 | 8 | 25 | 1 | |
| Time from Dx to first treatment, median (range), d | 27 (2, 164) | 42 (5, 164) | 12 (3, 40) | 23 (2, 101) | 56 | .048 |
| No. of therapies, median (range)* | 2 (1, 6) | 2 (1, 5) | 2 (1, 6) | 2 (1, 6) | 2 | .78 |
| First treatment† | ||||||
| HyperCVAD ± other | 8 (18) | 1 (10) | 2 (25) | 5 (20) | 0 (0) | — |
| ICE | 6 (14) | 2 (20) | 0 (0) | 4 (16) | 0 (0) | |
| CALGB 9111 | 5 (11) | 1 (10) | 2 (25) | 2 (8) | 0 (0) | |
| 7+3 ± other | 5 (11) | 0 (0) | 2 (25) | 3 (12) | 0 (0) | |
| CHOP ± other | 5 (11) | 2 (20) | 0 (0) | 2 (8) | 1 (100) | |
| Pralatrexate | 3 (7) | 0 (0) | 0 (0) | 3 (8) | 0 (0) | |
| HiDAC ± other | 2 (5) | 0 (0) | 1 (12) | 1 (4) | 0 (0) | |
| Gemcitabine based | 2 (5) | 1 (10) | 0 (0) | 1 (4) | 0 (0) | |
| Intensive ALL | 2 (5) | 1 (10) | 0 (0) | 1 (4) | 0 (0) | |
| Other | 6 (14) | 2 (20) | 1 (12) | 3 (12) | 0 (0) | |
| Type of first therapy | ||||||
| Lymphoid | 35 (77) | 10 (100) | 4 (50) | 20 (80) | 1 (100) | .039 |
| Myeloid | 9 (21) | 0 (0) | 4 (50) | 5 (20) | 0 (0) | |
| Intensity of first therapy | ||||||
| Not intensive | 9 (20) | 2 (20) | 2 (25) | 5 (20) | 0 (0) | .54 |
| Moderate | 11 (25) | 3 (30) | 0 (0) | 7 (28) | 1 (100) | |
| Intensive | 24 (55) | 5 (50) | 6 (75) | 13 (52) | 0 (0) |
| Variable . | Total . | Skin only . | Systemic only without skin . | Skin and systemic . | Incomplete staging . | P* . |
|---|---|---|---|---|---|---|
| N | 44 | 10 | 8 | 25 | 1 | |
| Time from Dx to first treatment, median (range), d | 27 (2, 164) | 42 (5, 164) | 12 (3, 40) | 23 (2, 101) | 56 | .048 |
| No. of therapies, median (range)* | 2 (1, 6) | 2 (1, 5) | 2 (1, 6) | 2 (1, 6) | 2 | .78 |
| First treatment† | ||||||
| HyperCVAD ± other | 8 (18) | 1 (10) | 2 (25) | 5 (20) | 0 (0) | — |
| ICE | 6 (14) | 2 (20) | 0 (0) | 4 (16) | 0 (0) | |
| CALGB 9111 | 5 (11) | 1 (10) | 2 (25) | 2 (8) | 0 (0) | |
| 7+3 ± other | 5 (11) | 0 (0) | 2 (25) | 3 (12) | 0 (0) | |
| CHOP ± other | 5 (11) | 2 (20) | 0 (0) | 2 (8) | 1 (100) | |
| Pralatrexate | 3 (7) | 0 (0) | 0 (0) | 3 (8) | 0 (0) | |
| HiDAC ± other | 2 (5) | 0 (0) | 1 (12) | 1 (4) | 0 (0) | |
| Gemcitabine based | 2 (5) | 1 (10) | 0 (0) | 1 (4) | 0 (0) | |
| Intensive ALL | 2 (5) | 1 (10) | 0 (0) | 1 (4) | 0 (0) | |
| Other | 6 (14) | 2 (20) | 1 (12) | 3 (12) | 0 (0) | |
| Type of first therapy | ||||||
| Lymphoid | 35 (77) | 10 (100) | 4 (50) | 20 (80) | 1 (100) | .039 |
| Myeloid | 9 (21) | 0 (0) | 4 (50) | 5 (20) | 0 (0) | |
| Intensity of first therapy | ||||||
| Not intensive | 9 (20) | 2 (20) | 2 (25) | 5 (20) | 0 (0) | .54 |
| Moderate | 11 (25) | 3 (30) | 0 (0) | 7 (28) | 1 (100) | |
| Intensive | 24 (55) | 5 (50) | 6 (75) | 13 (52) | 0 (0) |
Test excludes patients in the Incomplete staging column.
HyperCVAD, hyperfractionated cyclophosphamide, vincristine, doxorubicin, dexamethasone; ICE, ifosfamide, carboplatin, etoposide; 7+3, cytarabine, daunorubicin (or idarubicin); CALGB 9111, induction cyclophosphamide, daunorubicin, vincristine, prednisolone, asparaginase, and filgrastim; CHOP, cyclophosphamide, doxorubicin, vincristine, prednisolone; HIDAC, high-dose cytarabine; Intensive ALL, regimens used for high-risk pediatric acute lymphoblastic leukemia or Burkitt lymphoma (eg, SMILE [dexamethasone, methotrexate, ifosfamide, l-asparaginase, etoposide]); Other, targeted therapy or radiation.